CureVac Publishes Detailed Interim Phase 1 Data of its COVID-19 Vaccine Candidate, CVnCoV
- Data publication follows positive topline data reported November 2, 2020
- Full pre-print manuscript available on medRxiv
- Company to host conference call and webcast today at 5 p.m. CET (11 a.m. EST)
CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced publication of detailed interim Phase 1 data, following the reporting of positive topline data on November 2, 2020. The manuscript is available on medRxiv and will also be submitted for publication in a peer-reviewed journal.